A greater proportion of participants with type 2 diabetes achieve treatment targets with insulin degludec/liraglutide versus insulin glargine 100 units/mL at 26 weeks: DUAL VIII, a randomized trial designed to resemble clinical practice.

Sesti G, Bardtrum L, Dagdelen S, Halladin N, Haluzík M, Őrsy P, Rodríguez M, Aroda VR

Diabetes, obesity & metabolism29 Jan 2020Cited by 8 (Europe PMC)

PMID31903724PMCIDPMC7187233DOI10.1111/dom.13957PepBankPUB-31903724

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study7

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone7

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

01HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes uncontrolled on oral drugs, HbA1c reductions at 26 weeks were greater with the fixed-dose combination IDegLira than with insulin glargine U100.
In plain wordsIn adults with type 2 diabetes, the insulin degludec/liraglutide combination lowered HbA1c more than insulin glargine after 26 weeks.
Peptide
Liraglutide
Outcome
DecreaseHbA1c reduction at 26 weeks
Study
n = 1,012
Comparator
Insulin glargine 100 units/mL
Outcome group
Glycemic control · Metabolic and weight
Measurements
HbA1c change
−21.5 mmol/mol
IDegLira
HbA1c change
−16.4 mmol/mol
IGlar U100
Source sentences
Summary
After 26 weeks, glycated haemoglobin (HbA1c) reductions were greater with IDegLira versus IGlar U100 (-21.5 vs. -16.4 mmol/mol [-2.0 vs. -1.5%])
1 context sentence(design, population, supporting numbers)
Summary · context
Participants (N = 1012) with type 2 diabetes (T2D) uncontrolled on oral antidiabetic drugs (OADs) were randomized 1:1 to open-label IDegLira or IGlar U100.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3190372401
02HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes uncontrolled on oral drugs, a greater percentage reached HbA1c <53 mmol/mol with the fixed-dose combination IDegLira than with insulin glargine U100.
In plain wordsIn adults with type 2 diabetes, more people reached an HbA1c below 53 mmol/mol on the insulin degludec/liraglutide combination than on insulin glargine.
Peptide
Liraglutide
Outcome
IncreaseParticipants reaching HbA1c <53 mmol/mol
Study
n = 1,012
Comparator
Insulin glargine 100 units/mL
Outcome group
Glycemic control · Metabolic and weight
Measurements
Participants reaching HbA1c <53 mmol/mol
78.7%
IDegLira
Participants reaching HbA1c <53 mmol/mol
55.7%
IGlar U100
Source sentences
Summary
as was the percentage of participants achieving HbA1c <53 mmol/mol (78.7% vs. 55.7%)
1 context sentence(design, population, supporting numbers)
Summary · context
Participants (N = 1012) with type 2 diabetes (T2D) uncontrolled on oral antidiabetic drugs (OADs) were randomized 1:1 to open-label IDegLira or IGlar U100.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3190372402
03HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes uncontrolled on oral drugs, more participants reached HbA1c targets without weight gain and/or hypoglycaemia with the fixed-dose combination IDegLira than with insulin glargine U100.
In plain wordsIn adults with type 2 diabetes, more people reached HbA1c targets without weight gain or low sugar on insulin degludec/liraglutide than on insulin glargine.
Peptide
Liraglutide
Outcome
IncreaseHbA1c targets without weight gain and/or hypoglycaemia
Study
n = 1,012
Comparator
Insulin glargine 100 units/mL
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
and HbA1c targets without weight gain and/or hypoglycaemia.
1 context sentence(design, population, supporting numbers)
Summary · context
Participants (N = 1012) with type 2 diabetes (T2D) uncontrolled on oral antidiabetic drugs (OADs) were randomized 1:1 to open-label IDegLira or IGlar U100.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3190372403
04HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes uncontrolled on oral drugs, the estimated treatment difference in insulin dose significantly favoured the fixed-dose combination IDegLira over insulin glargine U100.
In plain wordsIn adults with type 2 diabetes, the insulin degludec/liraglutide combination needed a lower insulin dose than insulin glargine.
Peptide
Liraglutide
Outcome
DecreaseInsulin dose
Study
n = 1,012
Comparator
Insulin glargine 100 units/mL
Outcome group
Glycemic control · Metabolic and weight
Measurements
Estimated treatment difference in insulin dose
−13.01 U
IDegLira vs IGlar U100
Source sentences
Summary
Estimated treatment differences for insulin dose (-13.01 U)
1 context sentence(design, population, supporting numbers)
Summary · context
Participants (N = 1012) with type 2 diabetes (T2D) uncontrolled on oral antidiabetic drugs (OADs) were randomized 1:1 to open-label IDegLira or IGlar U100.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3190372404
05HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes uncontrolled on oral drugs, the estimated treatment difference in body weight change significantly favoured the fixed-dose combination IDegLira over insulin glargine U100.
In plain wordsIn adults with type 2 diabetes, body weight changed more favourably on the insulin degludec/liraglutide combination than on insulin glargine.
Peptide
Liraglutide
Outcome
DecreaseBody weight change
Study
n = 1,012
Comparator
Insulin glargine 100 units/mL
Outcome group
Body weight · Metabolic and weight
Measurements
Estimated treatment difference in body weight change
−1.57 kg
IDegLira vs IGlar U100
Source sentences
Summary
Estimated treatment differences for insulin dose (-13.01 U) and body weight change (-1.57 kg) significantly favoured IDegLira.
1 context sentence(design, population, supporting numbers)
Summary · context
Participants (N = 1012) with type 2 diabetes (T2D) uncontrolled on oral antidiabetic drugs (OADs) were randomized 1:1 to open-label IDegLira or IGlar U100.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3190372405
06HumanNot a test of Liraglutide aloneRandomized controlled trialSafety outcome
In adults with type 2 diabetes uncontrolled on oral drugs, the hypoglycaemia rate was 44% lower with the fixed-dose combination IDegLira than with insulin glargine U100.
In plain wordsIn adults with type 2 diabetes, the insulin degludec/liraglutide combination caused 44% fewer low blood sugar events than insulin glargine.
Peptide
Liraglutide
Outcome
DecreaseHypoglycaemia rate
Study
n = 1,012
Comparator
Insulin glargine 100 units/mL
Outcome group
Adverse events · Metabolic and weight
Measurements
Reduction in hypoglycaemia rate
44%
IDegLira vs IGlar U100
Source sentences
Summary
The hypoglycaemia rate was 44% lower with IDegLira versus IGlar U100.
1 context sentence(design, population, supporting numbers)
Summary · context
Participants (N = 1012) with type 2 diabetes (T2D) uncontrolled on oral antidiabetic drugs (OADs) were randomized 1:1 to open-label IDegLira or IGlar U100.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3190372406
07HumanNot a test of Liraglutide aloneRandomized controlled trialSafety outcome
In adults with type 2 diabetes uncontrolled on oral drugs, safety results were similar between the fixed-dose combination IDegLira and insulin glargine U100.
In plain wordsIn adults with type 2 diabetes, safety results were similar for the insulin degludec/liraglutide combination and insulin glargine.
Peptide
Liraglutide
Outcome
No significant changeOverall safety results
Study
n = 1,012
Comparator
Insulin glargine 100 units/mL
Outcome group
Adverse events · Whole body
Source sentences
Summary
Safety results were similar.
1 context sentence(design, population, supporting numbers)
Summary · context
Participants (N = 1012) with type 2 diabetes (T2D) uncontrolled on oral antidiabetic drugs (OADs) were randomized 1:1 to open-label IDegLira or IGlar U100.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3190372407

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.